Mirum Inks Japan License for Maralixibat With Takeda
September 21 2021 - 08:54AM
Dow Jones News
By Colin Kellaher
Mirum Pharmaceuticals Inc. on Tuesday said it signed an
exclusive licensing agreement with Takeda Pharmaceutical Co. for
maralixibat for rare pediatric liver diseases in Japan.
Mirum, a Foster City, Calif., biopharmaceutical company, said
Takeda would be responsible for development, regulatory approval
and commercialization of maralixibat in Japan for Alagille
syndrome, progressive familial intrahepatic cholestasis and biliary
atresia.
The U.S. Food and Drug Administration is currently reviewing
Mirum's application for maralixibat to treat cholestatic pruritus,
or itch, in patients with Alagille syndrome, with a target action
date of Sept. 29.
Mirum, which earlier this month filed for European approval of
maralixibat to treat cholestatic liver disease in patients with
Alagille syndrome, said it is looking for partners outside the U.S.
and Europe to expand the drug's global reach.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 21, 2021 08:39 ET (12:39 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Mar 2023 to Mar 2024